BRMEC10 Colloquium

The 10th Biomedical Research into ME Research Colloquium is taking place on 2 - 3 June 2021.
This year, due to the pandemic, the event will be held as a virtual event.

Welcome to BRMEC10

Day 1 of the Colloquium.
BRMEC10 is the tenth Biomedical Research into ME Colloquium organised by the charity.

All delegates to BRMEC10 will have received instructions on joining the meeting via email beforehand including information about the topics under discussion.
Each day will begin promptly at the published times.


Status Review

The Colloquium begins with an overview of the current status of research and has presentations from different areas.
Speakers are to be announced.

Epidemiology of ME (and Covid)

This section will look at the epidemiological evidence related to ME as well as reviewing the recent accruement of knowledge from COVID-19 research.

Hypotheses discussed include historical evidence for infectious agents including environmental and endogenous viruses and bacteria being associated with the onset and “outbreaks” of ME/CFS
and
in relation to COVID-19, genetically susceptible individuals are at increased risk of developing ME/CFS after SARS-CoV-2 infection resulting in an increase of symptoms fulfilling the diagnostic criteria of ME/CFS amongst infected individuals.

Speakers will represent these hypotheses which will then be discussed by delegates.

Professor Markku Partinen

Professor of Medicine, University of Helsinki, Finland

Professor Partinen is a neurologist and an internationally well-known opinion leader and expert in sleep research and sleep medicine.

He is currently working as Research Director of the Helsinki Sleep Clinic, Vitalmed Research Centre.
He works also at Haartman Institute, University of Helsinki, and at Akademiska Sjukhuset, University of Uppsala.

His expertise covers sleeping, nutrition (what to eat), and other aspects of modern life and well-being.
His current research projects include narcolepsy, Parkinson's disease, insomnia, traffic accidents and daytime sleepiness.

He has published more than 250 articles in peer-reviewed international journals, several books and chapters.

He was recently (Now 2015) elected as the new President of the Finnish Parkinson Association. Professor Partinen is also a member of the European ME Research Group (EMERG) and European ME Clinicians Council (EMECC).

Professor Friðbjörn Sigurðsson

Dr Friðbjörn Sigurdsson is Program Director Internal Medicine, Landspitali University Hospital in Rejkjavik, Iceland.Friðbjörn

CURRENT POSITIONS

  • Program Director Internal Medicine, Landspitali University Hospital (since October 1 2013)
  • Attending Medical Oncology, Landspitali University Hospital (since April 1 2001)
  • Attending Hematology, Landspitali University Hospital (part time since May 2009)
  • Medical Oncology and Hematology, Akureyri Hospital (part time since June 2010)

PREVIOUS POSITIONS

  • Chief Internal Medicine, Landspitali University Hospital
  • Chief Medical Council Landspitali University Hospital, Iceland
  • Attending, Oncology, Landspitali Hospital, Reykjavik, Iceland
  • Attending, Internal Medicine, Reykjavik City Hospital, Iceland
  • Læknasetrið – private practice, Reykjavik, Iceland
  • Chief Internal Medicine, Neskaupstadur Hospital, Iceland
  • Chief Internal Medicine Vestman Islands Hospital, Iceland
  • Stykkishólmur, heilsugæsla og sjúkrahús.

Professor Leonard Jason, DePaul University, Chicago,USA

Dr Leonard Jason has been among the most prolific of all ME/CFS researchers. For more than a decade, Dr Jason and his team at DePaul University’s Centre for Community Research in Chicago have worked to define the scope and impact of ME/CFS worldwide. Dr Jason is Vice President of the International Association for Chronic Fatigue Syndrome (now the IACFS/ME) and has been a key driver of CFS research since 1991, and is uniquely positioned to support collaboration between CFS researchers, patients, and government decision makers. His studies have shown that the direct and indirect costs of ME/CFS amount to $20 billion in the U.S. each year, and more than 1 million people suffer from ME/CFS as opposed to the estimated 20,000 people originally reported by the CDC (Centers for Disease Control and Prevention).

ANS and Autoimmunity

Hypothesis: Autonomic dysfunction and autoantibodies

Dr Jesper Mehlsen

Research Director, Coordinating Research Centre, Bispebjerg and Frederiksberg Hospital, Denmark
Co-chair European ME Research Group

Expertise
Autonomic nervous system; Heart rate and blood pressure control; Cardiovascular physiology and pathophysiology;
HPV vaccines and -complications
Main research areas Methods for the study of autonomic cardiovascular control; Mathematical modelling of cardiovascular control; Autoimmune response to vaccination; Mathematical modeling of the neuroinflammatory reflex
Current research Mathematical analysis of hemodynamic adaptations to the upright posture.
Mathematical analysis of hemodynamic response to Valsalva manoeuvre
Dynamic T-wave alterations and the autonomic nervous system
Mathematical analysis of cytokine response to LPS in humans
Autoimmunity in patients with possible side effects to HPV vaccination

Mitochondrial Dysfunction

Hypothesis: Mitochondrial metabolic dysfunction in ME

During this session, we will discuss potential causes of this mitochondrial metabolic dysfunction in ME, how it may relate to PEM and fatigue, and if attempts to revert it by pharmaceutical and diet manipulation will reverse or worsen ME symptom burden.

Associate Professor Rikke Olsen, Department of Clinical Medicine - Research Unit for Molecular Medicine, Aarhus University,Denmark

Scientific focus areas:
-Molecular genetic pathology and diagnostic of inborn errors of mitochondrial metabolism, focus on fatty acid oxidation and it’s co-factors (CoQ10 and riboflavin)
-Mitochondrial dysfunction in health and disease; focus on metabolic adaptation and mitochondrial redox signaling of cellular stress responses


Research training:
Main supervisor for 2 PhD students, and 1 PostDoc at the Health Faculty. Co-supervisor for a number of Bachelor and Master of Science students at the Faculty of Science and Technology. Active member of different university committees aiming at recruiting talented students for PhD Scholarships, and promoting creative and diverse research environments at Aarhus University. Course leader at theoretical PhD courses and experimental lab courses in molecular medicine.


Management experience:
-Responsible for the molecular diagnostic service at RUMM. Coordinate the lab work and communicate with biochemists and doctors from screening and metabolic labs around the world.
-6 years as scientific coordinator of the Graduate Program in Translational Molecular Medicines at the Faculty of Health, AU (arranged and chaired Annual Meetings and research seminars, planned and coordinated course programs).

Professor Karl Johan Tronstad

Professor Tronstad completed his graduate studies in biochemistry at the University of Bergen (UiB) in 2002. As postdoc at the Haukeland University Hospital, he studied bioactive compounds with the potential to modulate mitochondrial functions in cancer cells. In 2005 he was recruited to the Department of Biomedicine, UiB, where he started his research group to investigate metabolism and mitochondrial physiology. His laboratory seeks to better our understanding of how defective mitochondrial homeostasis may disturb cell physiology, and how this may be involved in mechanisms of cancer and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

Karl was involved with the recent paper to come from Bergen - Journal of Clinical Investigation Insight.

The Tronstad Lab investigates cell metabolism and mitochondrial biology.

Specialisms:
Metabolism, Cell biology, Mitochondria, Biochemistry

Dr. Bhupesh K Prusty, Principal Investigator, Institute for Virology and Immunobiology, Würzburg, Germany

Dr. Bhupesh Prusty is Group Leader in the Department of Microbiology at the University of Würzburg in Germany

Professor Tom Wileman, Quadram Institute, Norwich,UK


Career
2007- present Director, Biomedical Research Centre, University of East Anglia
1997-2005 Head of Department of Immunology and Pathology, Institute for Animal Health, Pirbright Laboratory, Woking, Surrey.
1994-1997 Head, Virus Cell Biology Group, Institute for Animal Health, Pirbright Laboratory, Woking, Surrey.
1991-1996 Assistant Professor, Department of Medicine, Harvard Medical School, Boston USA.
1991 - 1994 Assistant Professor, Division of Immunology, Beth Israel Hospital, Harvard Medical School, Boston, MA.
1988-1992 Claudia Adam's Barr Investigator in Cancer Research, Fellow of the Medical Foundation of the Charles King Trust and Basil O'Connor Scholar Award of the March of Dimes Research Foundation, Dept Molecular Immunology, Dana Farber Cancer Institute, Harvard Medical School
1982-1988 BBSRC NATO Fellow and Fellow of the Parker Francis Pulmonary Research Foundation. Department of Cell Biology, Washington University Medical School, St Louis.

The Wileman group at the Quadram Institute studies how viruses activate autophagy during cell entry and replication.

Dr Amolak Bansal

Consultant Immunologist, Spire Hospitals, Surrey, UK

Previously, Consultant in Immunology/Allergy and CFS/ME, Department of Immunology and Allergy, St Helier Hospital, Carshalton, Surrey.



Professor Aletta D. Kraneveld

Chair Interdisciplinary Translational Pharmacology| Division of Pharmacology | Department of Pharmaceutical Sciences | Utrecht Institute for Pharmaceutical Sciences, Utrecht University , Netherlands

Aletta Kraneveld, full professor Interdisciplinary Translational Pharmacology at the Faculty of Science and the faculty of Veterinary Medicine of the Utrecht University has published over 100 papers (H-index: 35).
Besides science, she is an active member of several (advisory) boards of national and international scientific organisations.
The Kraneveld group is focused on research into the role of the gut-immune-brain-axis in neurodevelopmental and neurodegenerative disorders including the interaction of microbiota and their fermentation products with the immune and nervous system.

Professor Elisa Oltra, Head of the Genetic Expression and Immunity group of the Faculty of Medicine at the Catholic University of Valencia, Spain

Elisa Oltra currently works at the Catholic University of Valencia, Valencia, Spain. Elisa does research in Cancer Research, Cell Biology and Genetics.


Professor Kristian Sommerfelt, Paediatric Neurologist at Haukeland University hospital in Bergen, Norway

Professor Kristian Sommerfelt is a paediatric neurologist at Haukeland University hospital in Bergen, NorwayKristian Sommerfelt

Professor Sommerfelt wrote the national guidelines (2019) for diagnosis, treatment and follow-up of ME/CFS children/ young people for the website NEL (Norsk Elektronisk Legehåndbok) - which is a web-based methods used the most by general practitioner doctors and also used extensively in hospitals. Over the last eight years he has given lectures and presentations at courses and conferences for health professionals and others in addition to teaching medical students.

Professor Maureen Hanson, Cornell University, USA

Maureen R. Hanson is Liberty Hyde Bailey Professor in the Department of Molecular Biology & Genetics. She received a B.S. degree at Duke University and a Ph.D. in Cell and Developmental Biology from Harvard University. After completing an NIH postdoctoral fellowship at Harvard, she joined the faculty of the Biology Department at University of Virginia. She moved to Cornell as Associate Professor and was promoted to Professor in 1991. She is presently a member of the graduate Fields of Genetics and Development, Plant Biology, and Biochemistry, Molecular, and Cell Biology. She has previously served as Associate Director of the Cornell Biotechnology Program and Director of the Cornell Plant Science Center. She is currently Director for the Center for Enervating Neuroimmune Disease.

Dr Linn Skjevling

SUMMARY - DAY 1

To be confirmed

Welcome to BRMEC10

Day 2 of the Colloquium.

OVERVIEW of DAY 2

To be confirmed

To be confirmed

IMMUNOGENETICS

Hypothesis -Immune and Immune genetic factors drive the development and progression of ME/CFS

HOST-MICROBE INTERACTIONS

Hypothesis: Host microbe interactions that affect the gut brain axis can predispose to ME/CFS

THERAPEUTICS (CURRENT/FUTURE)

Hypothesis: Therapeutic strategies should target the triggering and subsequent signalling events that cause the hallmark clinical symptoms of ME.

SUMMARY BRMEC10

Speakers:

  1. tbc

To be confirmed

Research tools for ME/CFS-related data and biospecimens

RTI International

Two new research tools developed by RTI International, the Data Management and Coordinating Center for the NIH-funded ME/CFS Collaborative Research Centers (CRCs) Network, are now available to help advance ME/CFS research by allowing researchers to access and share data and biospecimens.
An online data sharing platform that allows researchers to discover, share, and access data from multi-omic studies.
The platform was initially developed to support the ME/CFS Network CRCs that employ a variety of research methods (e.g., microbiome screens, RNA sequencing, mitochondrial assays, metabolomic assays) to identify potential biomarkers and study the underlying cause(s) of ME/CFS. mapMECFS allows researchers to search the contents of data sets across multiple studies, quickly compare results for specific molecules or markers of interest, and download relevant data to be used for exploration or validation studies. Additionally, mapMECFS encourages and facilitates sharing of new data by capturing key study metadata to make results easier to find.

An online, interactive search tool that allows researchers to query and request available biospecimens (e.g., DNA, RNA, urine, plasma, and peripheral blood mononuclear cells) based on specific demographic and clinical characteristics. The initial cohort, the Chronic Fatigue Initiative, was a research study supported by the Hutchins Family Foundation. Biospecimens and associated data were collected from 201 individuals with ME/CFS and 200 matched controls. The biospecimens are housed at the NINDS’ biomarker repository at Indiana University, and the data are hosted by RTI International. Investigators may also request access to just the clinical data for analysis. Additional cohorts’ biospecimens and datasets will be available in the future.

Open Discussion

this section is open to all delegates to discuss the preceding presentations

To be announced

To be announced

To be confirmed

To be confirmed

Dr Aimée Parker, Research Associate, Quadram Institute Bioscience, Norwich, UK

Dr Stafano Romano, Quadram Institute Bioscience, Norwich, UK

https://quadram.ac.uk/people/stefano-romano/

Assistant Professor Bradlee Heckmann, University of South Florida, Health, Neuroscience Institute, Byrd Alzheimer's Center, USA

Bradlee L. Heckmann is an American biologist and neuroimmunologist who is currently an investigator at the Byrd Alzheimer's Center and USF Health Neuroscience Institute and assistant professor in molecular medicine at the USF Health Morsani College of Medicine. Prior to his faculty appointment, Heckmann held the John H. Sununu Endowed Fellowship[1] in immunology at St. Jude Children's Research Hospital. Heckmann's research is focused on understanding the regulation of inflammatory processes in the central nervous system, with particular emphasis on neurodegenerative diseases including Alzheimer's Disease[2] and the role of the autophagy machinery in this setting. Source: Wikipedia

Assistant Professor Bradlee Heckmann, UMax-Delbrück-Centrum für Molekulare Medizin, Berlin, Germany

Dr. Wallukat led the research team that discovered the role of autoantibodies in dilated cardiomyopathy. He has been instrumental in investigating the role and function of autoantibodies in heart disease and other conditions at the Max-Delbrück-Center of Molecular Medicine in Berlin.

Dr. Wallukat also co-founded Affina Immuntechnik GmbH to to develop an adsorber for the new therapeutic option of immunoadsorption.

He is currently researching new ways to neutralize pathogenic autoantibodies without immunoadsorption.

Dr. Wallukat studied biology in Berlin and Leipzig and began his scientific work at the Institute of Cardiovascular Research of the Academy of Sciences with Prof. A. Wollenberger. After the unification of Germany he worked as head of a working group at the Max Delbrück Center of Molecular Medicine examining the immunology of cardiovascular diseases.

source:https://berlincures.de/the-team


Invest in ME Research Activity - Mainstreaming Research into ME


The charity does not only arrange and host research Colloquiums and Conferences.

Use our website references in the sitemap to view other work performed by Invest in ME Research.